LLY

1,040.03

+0.29%↑

JNJ

243.3

-0.53%↓

ABBV

231.41

+1.75%↑

NVS

162.81

+1.21%↑

MRK

121.33

+1.83%↑

LLY

1,040.03

+0.29%↑

JNJ

243.3

-0.53%↓

ABBV

231.41

+1.75%↑

NVS

162.81

+1.21%↑

MRK

121.33

+1.83%↑

LLY

1,040.03

+0.29%↑

JNJ

243.3

-0.53%↓

ABBV

231.41

+1.75%↑

NVS

162.81

+1.21%↑

MRK

121.33

+1.83%↑

LLY

1,040.03

+0.29%↑

JNJ

243.3

-0.53%↓

ABBV

231.41

+1.75%↑

NVS

162.81

+1.21%↑

MRK

121.33

+1.83%↑

LLY

1,040.03

+0.29%↑

JNJ

243.3

-0.53%↓

ABBV

231.41

+1.75%↑

NVS

162.81

+1.21%↑

MRK

121.33

+1.83%↑

Home・Aandelen Lijst・LifeStance Health Group Inc

LifeStance Health Group Inc

Gesloten

SectorGezondheidszorg

7.03 1.88

Buy Sell

Overzicht

Wijziging aandelenprijs

24u

Huidig

Min

7.02

Max

7.13

Belangrijke statistieken
By Trading Economics
Inkomsten	4.9M 1.1M
Verkoop	18M 364M
Winstmarge	0.296
Werknemers	7,996
EBITDA	10M 21M

Aanbevelingen
By TipRanks
Aanbevelingen	Strong Buy
12 Maanden Prognose	+29.87% upside

Dividenden
By Dow Jones
Volgende Winsten	25 feb 2026

Marktinformatie
By TradingEconomics
Marktkapitalisatie	736M 2.6B
Vorige openingsprijs	5.15
Vorige sluitingsprijs	7.03

Nieuwssentiment

By Acuity

100%

342 / 351 Rangschikking in Healthcare

Technische score

By Trading Central

Vertrouwen

Strong Bearish Evidence

5.39 / 6.595 Steun & Weerstand

LifeStance Health Group Inc Grafiek

Eerdere prestaties zijn geen betrouwbare indicator voor toekomstige resultaten.

Gerelateerd nieuws

15 feb 2026, 23:21 UTC

Acquisities, Fusies, Overnames

Qube Agrees to Takeover by MAM-Led Consortium Valuing Its Equity at $6.51 Billion

15 feb 2026, 23:45 UTC

Marktinformatie

Nikkei May Rise as Fears About AI Disruption Recede -- Market Talk

15 feb 2026, 23:40 UTC

Marktinformatie

Gold Falls on Possible Position Adjustments -- Market Talk

15 feb 2026, 23:06 UTC

Winsten

Thai Beverage: Spirits, Beer Businesses Posted Satisfactory EBITDA Growth, Alongside Profit Margin Expansion>Y92.SG

15 feb 2026, 23:04 UTC

Winsten

Thai Beverage 1Q Beer Business EBITDA THB4.64B, Up 4.7% on Year>Y92.SG

15 feb 2026, 23:04 UTC

Winsten

Thai Beverage 1Q Spirits Business EBITDA THB8.50B, Up 6.9% on Year >Y92.SG

15 feb 2026, 23:01 UTC

Winsten

Thai Beverage 1Q EBITDA THB16.75B, Up 1.8% on Year >Y92.SG

15 feb 2026, 23:01 UTC

Winsten

Thai Beverage 1Q FY Sales Revenue THB86.70B, Down 6.0% on Year>Y92.SG

15 feb 2026, 22:53 UTC

Acquisities, Fusies, Overnames

Qube: MAM-Led Offer Implies A$11.7 Billion Enterprise Value

15 feb 2026, 22:53 UTC

Acquisities, Fusies, Overnames

Qube: UniSuper to Transfer 15.07% Stake to Equivalent Ownership of Consortium Holding Structure

15 feb 2026, 22:52 UTC

Acquisities, Fusies, Overnames

Qube Shareholders to Receive A$5.20/Share in Cash

15 feb 2026, 22:52 UTC

Acquisities, Fusies, Overnames

Qube Holdings Agrees to Takeover by Macquarie Asset Management-Led Consortium

15 feb 2026, 22:22 UTC

Acquisities, Fusies, Overnames

BlueScope CEO Tania Archibald Speaking on a Call With Media

15 feb 2026, 22:17 UTC

Acquisities, Fusies, Overnames

BlueScope CEO: Stresses Whyalla Project Would Have to Make Sense to Shareholders

15 feb 2026, 22:16 UTC

Acquisities, Fusies, Overnames

BlueScope CEO: Some Job Cuts Inevitable to Ensure Company is Competitive

15 feb 2026, 22:14 UTC

Acquisities, Fusies, Overnames

BlueScope CEO: Higher Returns Tied to End of Capital Investment Program

15 feb 2026, 22:14 UTC

Acquisities, Fusies, Overnames

BlueScope Steel CEO: Higher Returns After Rebuffed Takeover Bid a 'Natural Coincidence'

15 feb 2026, 20:48 UTC

Winsten

BlueScope: Will Now Target Net Debt of Up to A$1.5 Billion; Will Surpass as Needed

15 feb 2026, 20:47 UTC

Winsten

BlueScope: Expects Full Benefits of Further A$150M Cost Savings in FY 2027

15 feb 2026, 20:46 UTC

Winsten

BlueScope: Recorded Net Annualized Cost Improvements of A$190 Million in 1H

15 feb 2026, 20:45 UTC

Winsten

BlueScope Expects a One-Third Lower 2H Result From Asia Business Vs 1H

15 feb 2026, 20:44 UTC

Winsten

BlueScope Expects 15% Higher 2H Result From North America Business Vs 1H

15 feb 2026, 20:44 UTC

Winsten

BlueScope Expects Lower 2H Result From Australia Business Vs 1H

15 feb 2026, 20:43 UTC

Winsten

BlueScope Expects 2H Underlying Ebit of A$620 Million-A$700 Million

15 feb 2026, 20:42 UTC

Winsten

BlueScope Net Debt A$2.2 Million at Dec. 31

15 feb 2026, 20:42 UTC

Winsten

BlueScope 1H Underlying Ebit A$557.5 Million, Up 81% On-Year

15 feb 2026, 20:41 UTC

Winsten

BlueScope 1H Underlying Ebitda A$915.3 Million, Up 39% On-Year

15 feb 2026, 20:40 UTC

Winsten

BlueScope 1H Underlying Profit A$382.0 Million Vs A$176.4 Million Year Prior

15 feb 2026, 20:40 UTC

Winsten

BlueScope 1H Sales Revenue From Continuing Ops A$8.22 Billion, Up 4% On-Year

15 feb 2026, 20:39 UTC

Winsten

BlueScope Intends to Spend A$310 Million on Buyback, Or Other Returns if Share Repurchases Limited

Peer Vergelijking

Prijswijziging

LifeStance Health Group Inc Prognose

Koersdoel

By TipRanks

29.87% opwaarts potentieel

12 Maanden Prognose

Gemiddelde 9.13 USD 29.87%

Hoogste 11 USD

Laagste 8 USD

Gebaseerd op 5 Wall Street-analisten die 12-maands prijsdoelen bieden voor LifeStance Health Group Inc - Dist. in de afgelopen 3 maanden.

Beoordelingsconsensus

By TipRanks

Strong Buy

5 ratings

Buy

Hold

Sell

Gebaseerd op 5 analisten die aandelenratings hebben gegeven aan LifeStance Health Group Inc - Dist in de afgelopen 3 maanden.

Technische score

By Trading Central

5.39 / 6.595Steun & Weerstand

Recent bearish events outweigh bullish events.

All events are bearish.

Financieel

Verkoop- en administratiekosten

Bedrijfskosten

Winst voor belastingen

Verkoop

Kosten van verkopen

Brutowinst op verkopen

Rente-uitgaven op schulden

EBITDA

Operationele winst

Over LifeStance Health Group Inc

LifeStance Health Group, Inc., through its subsidiaries, provides outpatient mental health services to children, adolescents, adults, and geriatrics in the United States. The company offers patients a suite of mental health services, including psychiatric evaluations and treatment, psychological, and neuropsychological testing, as well as individual, family, and group therapy. It treats a range of mental health conditions, including anxiety, depression, bipolar disorder, eating disorders, psychotic disorders, and post-traumatic stress disorder. In addition, the company operates an outpatient mental health platform, as well as offers patient care virtually through its online delivery platform or in-person at its centers. LifeStance Health Group, Inc. was founded in 2017 and is headquartered in Scottsdale, Arizona.